Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer.
- Author:
Min YAN
1
;
San-Tai SONG
;
Ze-Fei JIANG
;
Shao-Hua ZHANG
;
Xiao-Qing LIU
;
Jian-Ming XU
;
Tao WANG
;
Wei-Dong LUO
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; therapeutic use; Bone Neoplasms; secondary; therapy; Breast Neoplasms; mortality; therapy; Female; Humans; Prognosis; Retrospective Studies; Survival Rate; Treatment Failure
- From: Chinese Journal of Oncology 2004;26(3):177-180
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer.
METHODSA total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed.
RESULTSThe response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% (P = 0.687), and the total response rates were 27.1% and 25.0% (P = 0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9% and 36.6% (P = 0.437), as second-line were 47.8% and 24.2% (P = 0.033), in total treatments were 47.5% and 27.7% (P = 0.001). The median interval to treatment failure (TTF) was 5 months and 2 months (P < 0.001), and that to progression (TTP) was 5 and 2.5 months (P < 0.001) in endocrine therapy and chemotherapy group, respectively.
CONCLUSIONEndocrine therapy is superior to chemotherapy for bone metastasis of breast cancer.
